• H. Lundbeck A/S, of Copenhagen, Denmark, reported post hoc analyses at the European College of Neuropsychopharmacology meeting in Vienna, Austria, showing that asenapine achieved significant control of mixed episodes in bipolar I disorder compared to placebo. Asenapine is a tetracyclic antipsychotic therapy.